|
Online Database of Chemicals from Around the World | 产品搜索 | 产品提交 | 产品推广 | |
网站主页 >> 化工产品目录 >> 胰淀素 (1-13) (人)>> 市场分析报告 |
胰淀素 (1-13) (人)市场分析报告 |
|
Global Market Report of AMYLIN (1-13) (HUMAN) (CAS 198328-30-2) December 2024 Global Market Report of AMYLIN (8-37) (HUMAN) (CAS 135702-23-7) December 2024 Amylin Pharmaceuticals, Inc. Fundamental Company Report Including Financial, SWOT, Competitors and Industry Analysis Amylin Pharmaceuticals, Inc., a biopharmaceutical company, engages in ... program. Metreleptin is the recombinant form of human leptin, a naturally occurring protein hormone ... Islet Amyloid Polypeptide (Amylin or Diabetes Associated Peptide or Insulinoma Amyloid Peptide or IAPP) - Pipeline Review, H2 2018 Islet Amyloid Polypeptide (Amylin or Diabetes Associated Peptide or Insulinoma Amyloid Peptide or IAPP) - Pipeline Review, H2 2018 SUMMARY Islet Amyloid Polypeptide (Amylin or Diabetes Associated Peptide or Insulinoma Amyloid Peptide or IAPP) pipeline ... Islet Amyloid Polypeptide (Amylin or Diabetes Associated Peptide or Insulinoma Amyloid Peptide or IAPP) - Pipeline Review, H1 2018 Islet Amyloid Polypeptide (Amylin or Diabetes Associated Peptide or Insulinoma Amyloid Peptide or IAPP) - Pipeline Review, H1 2018 SUMMARY Islet Amyloid Polypeptide (Amylin or Diabetes Associated Peptide or Insulinoma Amyloid Peptide or IAPP) pipeline ... Global Market Report of AMYLIN, HUMAN (CAS 122384-88-7) December 2024 Islet Amyloid Polypeptide (Amylin or Diabetes Associated Peptide or Insulinoma Amyloid Peptide or IAPP) - Drugs in Development, 2021 Islet Amyloid Polypeptide (Amylin or Diabetes Associated Peptide or Insulinoma Amyloid Peptide or IAPP) - Drugs in Development, 2021 SUMMARY Islet Amyloid Polypeptide (Amylin or Diabetes Associated Peptide or Insulinoma Amyloid Peptide or IAPP) pipeline ... Islet Amyloid Polypeptide (Amylin or Diabetes Associated Peptide or Insulinoma Amyloid Peptide or IAPP) Drugs In Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update Islet Amyloid Polypeptide (Amylin or Diabetes Associated Peptide or Insulinoma Amyloid Peptide or IAPP) Drugs In Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update SUMMARY Islet Amyloid Polypeptide ( ... Diabetes Drug Market, Oral (DPP IV Inhibitor, SGLT-2, Alpha Glucosidase Inhibitor, Biguanide) Injection (Glucagon-like peptide (GLP) 1 agonist, Amylin Receptor Agonist), Insulin (Rapid – Acting Insulin, Long Acting Insulin, Premixed Insulin), Regions (United States, Europe, Japan, China, India, Brazil), Companies (Novo Nordisk, Merck & Co, Eli Lilly, AstraZeneca, Johnson & Johnson, Boehringer Ingelheim) Global diabetes drug market is expected to surpass US$ 76 Billion by the end of year 2024. Rising global diabetes prevalence like Type 1 diabetes and Type 2 diabetes is the major reason for growth of diabetes drug market. Type 2 diabetes is on the rise ... Injectable Anti diabetic Drugs Market Size, Trends, Analysis, and Outlook By Insulin, Basal or Long-acting Insulins, Bolus or Fast-acting Insulins, Traditional Human Insulins, Combination Insulins, Biosimilar Insulins), By Glucagon-like peptide-1 (GLP-1) agonists drugs, Dulaglutide, Exenatide, Liraglutide, Lixisenatide, Semaglutide), by Country, Segment, and Companies, 2024-2032 ... or Fast-acting Insulins, Traditional Human Insulins, Combination Insulins, Biosimilar ... , GLP-1 receptor agonists, and amylin analogs. Additionally, advancements in drug ... or Fast-acting Insulins Traditional Human Insulins Combination Insulins Biosimilar ... Alexandria Real Estate Equities Inc. Fundamental Company Report Including Financial, SWOT, Competitors and Industry Analysis ... tenants included Novartis AG, ZymoGenetics, Inc., Human Genome Sciences, Inc; GlaxoSmithKline, Massachusetts ... of Technology, Theravance, Inc., Genentech, Inc., Amylin Pharmaceuticals, Inc., Amgen, Inc., and ... Eli Lilly & Co. Fundamental Company Report Including Financial, SWOT, Competitors and Industry Analysis ... ; and Humatrope, for the treatment of human growth hormone deficiency and certain ... . The company co-promotes Byetta with Amylin Pharmaceuticals, Inc. in the United States ... Global Anti-Obesity Drugs (Anti-obesity Medication) Market Growth 2023-2029 ... one of the fundamental processes of the human body, weight regulation, by altering either ... Ingelheim Bayer AG AstraZeneca Arena Pharmaceuticals Amylin Alizyme Key Questions Addressed in this ... Global Anti-obesity Drugs Market 2024 by Manufacturers, Regions, Type and Application, Forecast to 2030 ... one of the fundamental processes of the human body, weight regulation, by altering either ... Roche GlaxoSmithKline Orexigen Therapeutics Vivus Amylin Alizyme Boehringer Ingelheim Eisai Market ... Global Anti Obesity Drugs Anti obesity Medication Market Research Report 2023(Status and Outlook) ... one of the fundamental processes of the human body, weight regulation, by altering either ... Ingelheim Bayer AG AstraZeneca Arena Pharmaceuticals Amylin Alizyme Market Segmentation (by Type) by Drug ... Global Anti-Obesity Drugs (Anti-obesity Medication) Market Research Report 2024(Status and Outlook) ... one of the fundamental processes of the human body, weight regulation, by altering either ... Ingelheim Bayer AG AstraZeneca Arena Pharmaceuticals Amylin Alizyme Market Segmentation (by Type) by Drug ... Global Anti-Obesity Drugs (Anti-obesity Medication) Market Research Report 2024, Forecast to 2032 ... one of the fundamental processes of the human body, weight regulation, by altering either ... Ingelheim Bayer AG AstraZeneca Arena Pharmaceuticals Amylin Alizyme Market Segmentation (by Type) Prescription ... Global Anti-obesity Drugs Market Research Report 2024, Forecast to 2032 ... one of the fundamental processes of the human body, weight regulation, by altering either ... Roche GlaxoSmithKline Orexigen Therapeutics Vivus Amylin Alizyme Boehringer Ingelheim Eisai Market ... Anti-obesity Drugs Market, Global Outlook and Forecast 2022-2028 ... one of the fundamental processes of the human body, weight regulation, by altering ... GlaxoSmithKline, Orexigen Therapeutics, Vivus and Amylin, etc. In 2021, the global top ... GlaxoSmithKline Orexigen Therapeutics Vivus Amylin Alizyme Boehringer Ingelheim Eisai Diabetes - KOL Insight and Consensus Outlook Modules ... ’s Eperzan (albiglutide) and BMS/AZ/Amylin’s Bydureon (exanatide) but meaningful ... ; Bristol-Myers Squibb/AstraZeneca/Amylin) forecast Bydureon (exenatide once- ... ) forecast Eperzan (albiglutide; GlaxoSmithKline/Human Genome Sciences) forecast LY2189265 ( ... |